Article content material
MANAMA, Bahrain, Dec. 02, 2023 (GLOBE NEWSWIRE) — Bahrain has develop into the second nation on the planet and the primary within the Center East to approve the usage of CASGEVY (exagamglogene autotemcel) for the remedy of sufferers with sickle cell illness and transfusion-dependent beta-thalassemia. The remedy was developed by Vertex Prescribed drugs and CRISPR Therapeutics, after conducting a collection of profitable scientific trials within the UK, US, France, Italy, and Germany, amongst others.
Article content material
Following the UK MHRA’s authorisation to make use of CASGEVY, Bahrain is the second nation on the planet and the primary within the area to approve this remedy.
Article content material
This extraordinary growth opens up new potentialities for medical developments and reinforces Bahrain’s dedication to pioneering healthcare options, providing a greater high quality of life for sufferers with these blood issues.
CRISPR (Clustered Commonly Interspaced Brief Palindromic Repeats) is a revolutionary gene-editing method that holds immense potential for treating a variety of genetic issues. By harnessing the ability of CRISPR, scientists can transfuse sufferers with their very own edited stem cells to provide absolutely functioning hemoglobin and supply hope for sufferers with situations that have been beforehand thought of untreatable, akin to sickle cell anemia.
By embracing the revolutionary remedy, Bahrain is just not solely demonstrating its dedication to bettering the well being and well-being of its individuals but additionally positioning itself on the forefront of medical developments within the area.
Article content material
Her Excellency, Dr Jaleela Jawad Minister of Well being acknowledged “This authorization showcases Bahrain’s progressive method to healthcare and its willpower to stay on the forefront of scientific breakthroughs.”
The affirmation of approval by the Nationwide Well being Regulatory Authority (NHRA) of the Kingdom of Bahrain, adopted thorough evaluation and evaluation undertaken by NHRA. As we speak, sickle-cell sufferers in Bahrain endure from the very restricted globally obtainable choices of remedy. Past bone marrow transplant, one of many solely cures obtainable for sickle cell illness is the usage of genetic modifying remedy, CASGEVY.
Commenting on this, Dr. Ahmed Alansari CEO of the Nationwide Well being Regulatory Authority in Bahrain stated, “The approval of the usage of CASGEVY in Bahrain marks a big turning level within the cluster of remedies on supply to Bahrainis. It’s a testomony to the nation’s visionary management, dedication to innovation, and unwavering dedication to bettering the lives of its residents, whereas ushering within the highest high quality of well being care and wellbeing for them.”
For extra info, please contact the Nationwide Communication Centre of the Kingdom of Bahrain on communication@ncc.gov.bh.
Share this text in your social community